Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.
Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 3 and 2 respectively.
Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology).
- The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Polycythemia Vera - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycythemia Vera - Overview
Polycythemia Vera - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Polycythemia Vera - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycythemia Vera - Companies Involved in Therapeutics Development
AbbVie Inc
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Italfarmaco SpA
Nerviano Medical Sciences Srl
PharmaEssentia Corp
SELLAS Life Sciences Group Inc
Polycythemia Vera - Drug Profiles
anagrelide hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idasanutlin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycythemia Vera - Dormant Projects
Polycythemia Vera - Discontinued Products
Polycythemia Vera - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials
Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting
Dec 10, 2017: PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017
Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
Nov 27, 2017: Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting
Jun 25, 2017: AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
Mar 14, 2017: AOP Orphan Pharmaceuticals announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera
Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016
Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation
Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012
May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition
Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Polycythemia Vera, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Polycythemia Vera - Pipeline by AbbVie Inc, H1 2018
Polycythemia Vera - Pipeline by Bristol-Myers Squibb Co, H1 2018
Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Polycythemia Vera - Pipeline by Gilead Sciences Inc, H1 2018
Polycythemia Vera - Pipeline by Italfarmaco SpA, H1 2018
Polycythemia Vera - Pipeline by Nerviano Medical Sciences Srl, H1 2018
Polycythemia Vera - Pipeline by PharmaEssentia Corp, H1 2018
Polycythemia Vera - Pipeline by SELLAS Life Sciences Group Inc, H1 2018
Polycythemia Vera - Dormant Projects, H1 2018
Polycythemia Vera - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Polycythemia Vera, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Cancer Immunomodulator Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 95
The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 158
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 131
According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 125
According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period.
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
Published: 27-Dec-2023 Price: US 3350 Onwards Pages: 112
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Dec-2023 Price: US 3380 Onwards Pages: 101
Market Overview of Global Cancer Gene Therapy market:
According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
Published: 25-Dec-2023 Price: US 3350 Onwards Pages: 85
CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively.
The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
Global Kaposi Sarcoma Market Status and Outlook 2023-2028
Published: 22-Dec-2023 Price: US 3160 Onwards Pages: 107
Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 21-Dec-2023 Price: US 3380 Onwards Pages: 118
Market Overview of Global Cancer Immunomodulator market:
According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
